BMEA Historical PE Ratio Notes

— Biomea Fusion (ticker symbol BMEA) is a clinical-stage biopharmaceutical company focused on developing covalent small molecule therapies to treat genetically defined cancers & metabolic diseases, such as diabetes. Its proprietary FUSION System platform enables the design of irreversible inhibitors targeting specific proteins linked to disease progression. Since BMEA is in a pre-revenue phase—meaning it is not yet generating earnings from product sales—its historical price to earnings (pe) ratio data will be either negative or not meaningful in most periods. This is typical for early-stage biotech firms, where investor interest & valuation are driven more by pipeline progress, clinical trial milestones, & expectations of future commercialization rather than current profitability. As you review BMEA's historical pe ratio charts & tables, keep in mind that any high, negative, or undefined pe ratios simply reflect the company's ongoing investments in R&D and lack of established revenue, rather than operational inefficiency or poor performance. For Biomea Fusion, historical pe ratios are best interpreted as a measure of market sentiment about future growth potential instead of a traditional gauge of the company's earnings power.

On this page we presented the BMEA Historical PE Ratio information for Biomea Fusion' stock. The average BMEA historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 1.0. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average BMEA historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this BMEA historical PE result, against the recent PE: when this page was posted on 5/15/2026, the most recent closing price for BMEA had been 1.35, and the most recent quarterly earnings result, annualized, was 1.08. Meanwhile, the most recent TTM earnings summed to NA. From these numbers, we calculate the recent BMEA PE on 5/15/2026 based on annualized quarterly EPS was 1.2. Based on BMEA's history, that recent PE is elevated relative to the historical average, with the recent PE 20.0% higher than the historical average PE across our data set for Biomea Fusion.

For self directed investors doing their due diligence on BMEA or any other given stock, valuation analysis for BMEA can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Biomea Fusion PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for BMEA. Thanks for visiting, and the next time you need to research BMEA Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.